Navigation Links
Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
Date:12/1/2008

t, rotating and early riser), travel across time zones, delayed sleep phase syndrome, advanced phase syndrome and the non-24-hour sleep-wake syndrome in the blind. These disorders represent a large public health problem and, as presented in the 2006 Institute of Medicine (IOM) report on sleep disorders(5), the annual economic impact of sleep problems due to night shift work alone is estimated to exceed $65 billion.

The novel circadian regulator tasimelteon holds promise for the treatment of patients with misalignments of the body clock. The work presented in The Lancet examines the potential application in sleep disorders. Additional clinical trials will have to be conducted to examine the role of circadian regulators in the treatment of other disorders such as depression, nondipper hypertension(3)(4), and others.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failur
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
3. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
4. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
5. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
6. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
9. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
10. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
11. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
(Date:7/30/2014)... 2014  Hospira, Inc. (NYSE: HSP ... and infusion technologies, today reported results for the ... for the quarter were $1.1 billion and adjusted* ... exclude specified items as described later in this ... U.S. Generally Accepted Accounting Principles (GAAP) basis, second-quarter ...
(Date:7/30/2014)... July 30, 2014   Epic Sciences, Inc. ... designs and develops novel diagnostics to personalize and ... today the completion of a $30 million Series ... investors RusnanoMedInvest (RMI) and Arcus Ventures, existing investors ... Investments, as well as undisclosed individual investors. With ...
Breaking Medicine Technology:Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3
(Date:7/30/2014)... WalkingSticksandCane.com has just received the latest shipment ... the new European fashions and the men will love the ... are from one from one of the major manufacturers in ... unique and offer the consumer the ability to have many ... some of the rarest and most sought after walking sticks ...
(Date:7/30/2014)... Babies who are born with severe combined immunodeficiency (SCID) ... stem cells, according to experts led by Memorial Sloan ... the development of transplant protocols. Their review will be ... New England Journal of Medicine . , SCID is ... system to severely malfunction. When this breakdown occurs, babies ...
(Date:7/30/2014)... “United States Orthopedic Braces and Supports Market Outlook ... Orthopedic Braces and Supports market. The report provides value, in ... price data (in US dollars), within market categories:, ... Braces and Supports , Spinal Braces and Supports ... , Orthotics is a specialty within the medical field concerned ...
(Date:7/30/2014)... Washington, DC (PRWEB) July 30, 2014 ... PhD, RN, CNE, ANEF, who since September 2013 has ... Nursing , became the new dean of the College ... 14. The move marries her leadership of the NLN, ... one of the top-ranked academic nursing and research institutions ...
(Date:7/30/2014)... Sugar Land, TX (PRWEB) July 30, 2014 ... pharmacy recently announced their plans to move to a new ... been announced, but they will be moving soon. , MedX ... 6302 W Broadway in Pearland, TX 77581. This is the ... than their current one and will include a drive thru ...
Breaking Medicine News(10 mins):Health News:European Walking Sticks from WalkingSticksandCane.com 2Health News:Transplantation shown to be highly effective in treating immune deficiency in children 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:MedX Pharmacy Relocates to New Facility 2
... CVCTA Education, the leader in,physician education for cardiac ... helps physicians reduce the radiation dose to patients ... doses during CTA,are in the low dose ranges, ... creating a health risk. However, if physicians and ...
... 2008, thousands of dental research scientists, students, and educators from ... American Association for Dental Research (AADR) holds its 37th Annual ... This press kit contains: , a background paper ... the meeting, , releases on the Featured Presentations, , ...
... The National Institute of Dental and Craniofacial Research (NIDCR), ... its 60th anniversary with three special symposia during the ... Research (AADR), convening here today at the Hilton Anatole ... (Thursday, April 3), Looking Toward the ...
... patients receive x-rays; however most believed,they were not ... degree of risk,varies with each case., HARRISBURG, ... radiation) in over 90 cases reported to the,Pennsylvania ... patients had,indicated they were not pregnant, according to ...
... BIRMINGHAM, Ala., March 27 Surgical Care,Affiliates ("SCA") today ... 1:00 p.m. Eastern Time on Monday, March 31, 2008, ... 2007. Please go to SCA,s,Intralinks website to obtain dial-in ... Audra Szush at (205) 545.2769 or by e-mail at,audra.szush@scasurgery.com ...
... Screening for cardiovascular problems in elite-level football players should ... of college and professional players. Mayo Clinic physicians based ... of the cardiovascular health of 233 retired National Football ... that 82 percent of NFL players under age 50 ...
Cached Medicine News:Health News:CVCTA Education Announces New LOW DOSE Initiative for CT Angiograms 2Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 2Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 3Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 4Health News:Mayo Clinic finds retired NFL players at increased risk for heart problems 2Health News:Mayo Clinic finds retired NFL players at increased risk for heart problems 3
... Botox therapy and nerve block procedures, ... needle has a precisely machined Trocar ... an attached 61-cm (24-in) lead wire. ... Single patient use only. A starter ...
Shielding's Flex Back Apron is one of our most popular. Similar to the Velcro Adjustable but with elastic back panels for additional support and comfort....
Shielding's Fast Wrap Apron offers both comfort and ease of wearing. Adjustable back shoulder strap keeps apron snug. No ties or buckles....
... Shielding's new Breast ... designed to provide extra ... area. The adjustable velcro ... quick, comfortable fit, plust ...
Medicine Products: